LYON, France, April 9 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP - News), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution of a wide portfolio of minimally invasive medical devices primarily for the treatment of urological diseases announced it has concluded its prior US clinical relationship with HealthTronics. Under terms of the agreement, HealthTronics will provide cash and equipment to EDAP with a total value of approximately $2.0 million. EDAP also regains full rights for its global leading Ablatherm-HIFU prostate cancer therapy device in the important US medical market, pending future FDA approval.
